1. Home
  2. ESCA vs IKT Comparison

ESCA vs IKT Comparison

Compare ESCA & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Escalade Incorporated

ESCA

Escalade Incorporated

HOLD

Current Price

$20.13

Market Cap

257.2M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.41

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESCA
IKT
Founded
1922
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
257.2M
220.5M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
ESCA
IKT
Price
$20.13
$2.41
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
44.0K
755.7K
Earning Date
04-30-2026
03-26-2026
Dividend Yield
3.50%
N/A
EPS Growth
6.45
57.76
EPS
1.00
N/A
Revenue
$180,541,000.00
N/A
Revenue This Year
$4.15
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.82
N/A
Revenue Growth
2.71
N/A
52 Week Low
$11.41
$1.33
52 Week High
$23.07
$2.53

Technical Indicators

Market Signals
Indicator
ESCA
IKT
Relative Strength Index (RSI) 49.44 62.29
Support Level $17.63 $1.63
Resistance Level $21.32 $2.53
Average True Range (ATR) 1.12 0.13
MACD -0.11 -0.01
Stochastic Oscillator 36.53 73.42

Price Performance

Historical Comparison
ESCA
IKT

About ESCA Escalade Incorporated

Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: